TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Vukašin, Tamara
AU  - Velija-Ašimi, Zelija
AU  - Bureković, Azra
AU  - Zdravković, Marija
AU  - Andrić, Zoran
AU  - Branković, Marija
AU  - Crevar-Marinović, Slobodanka
AU  - Mandić, Tatjana
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Livadas, Sarantis
AU  - Mastorakos, George
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4307
AB  - Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Polycystic Ovary Syndrome: A Contemporary Clinical Approach
VL  - 27
DO  - 10.2174/1381612827666210119104721
SP  - 1
EP  - 9
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Vukašin, Tamara and Velija-Ašimi, Zelija and Bureković, Azra and Zdravković, Marija and Andrić, Zoran and Branković, Marija and Crevar-Marinović, Slobodanka and Mandić, Tatjana and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Livadas, Sarantis and Mastorakos, George",
year = "2021",
abstract = "Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Polycystic Ovary Syndrome: A Contemporary Clinical Approach",
volume = "27",
doi = "10.2174/1381612827666210119104721",
pages = "1-9"
}

Bjekić-Macut, J., Vukašin, T., Velija-Ašimi, Z., Bureković, A., Zdravković, M., Andrić, Z., Branković, M., Crevar-Marinović, S., Mandić, T., Stanojlović, O., Vojnović-Milutinović, D., Livadas, S.,& Mastorakos, G.. (2021). Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design
Bentham Science Publishers., 27, 1-9.
https://doi.org/10.2174/1381612827666210119104721

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, Branković M, Crevar-Marinović S, Mandić T, Stanojlović O, Vojnović-Milutinović D, Livadas S, Mastorakos G. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design. 2021;27:1-9.
doi:10.2174/1381612827666210119104721 .

Bjekić-Macut, Jelica, Vukašin, Tamara, Velija-Ašimi, Zelija, Bureković, Azra, Zdravković, Marija, Andrić, Zoran, Branković, Marija, Crevar-Marinović, Slobodanka, Mandić, Tatjana, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Livadas, Sarantis, Mastorakos, George, "Polycystic Ovary Syndrome: A Contemporary Clinical Approach" in Current Pharmaceutical Design, 27 (2021):1-9,
https://doi.org/10.2174/1381612827666210119104721 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Mladenović, Violeta
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Andrić, Zoran
PY  - 2020
UR  - http://www.eurekaselect.com/172346/article
UR  - http://www.ncbi.nlm.nih.gov/pubmed/31146668
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3969
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.
PB  - Bentham Science Publishers Ltd.
T2  - Current Hypertension Reviews
T1  - Hypertension in Polycystic Ovary Syndrome: Novel Insights.
IS  - 1
VL  - 16
DO  - 10.2174/1573402115666190531071422
SP  - 55
EP  - 60
ER  - 

@article{
author = "Macut, Đuro and Mladenović, Violeta and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Andrić, Zoran",
year = "2020",
abstract = "Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulinsensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.",
publisher = "Bentham Science Publishers Ltd.",
journal = "Current Hypertension Reviews",
title = "Hypertension in Polycystic Ovary Syndrome: Novel Insights.",
number = "1",
volume = "16",
doi = "10.2174/1573402115666190531071422",
pages = "55-60"
}

Macut, Đ., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D.,& Andrić, Z.. (2020). Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews
Bentham Science Publishers Ltd.., 16(1), 55-60.
https://doi.org/10.2174/1573402115666190531071422

Macut Đ, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights.. in Current Hypertension Reviews. 2020;16(1):55-60.
doi:10.2174/1573402115666190531071422 .

Macut, Đuro, Mladenović, Violeta, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Andrić, Zoran, "Hypertension in Polycystic Ovary Syndrome: Novel Insights." in Current Hypertension Reviews, 16, no. 1 (2020):55-60,
https://doi.org/10.2174/1573402115666190531071422 . .

TY  - JOUR
AU  - Macut, Đuro
AU  - Bjekić-Macut, Jelica
AU  - Livadas, Sarantis
AU  - Stanojlović, Olivera
AU  - Hrnčić, Dragan
AU  - Rašić-Marković, Aleksandra
AU  - Vojnović-Milutinović, Danijela
AU  - Mladenović, Violeta
AU  - Andrić, Zoran
PY  - 2019
UR  - http://www.eurekaselect.com/169068/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3308
AB  - Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.
T2  - Current Pharmaceutical Design
T1  - Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome
IS  - 38
VL  - 24
DO  - 10.2174/1381612825666190117100751
SP  - 4593
EP  - 4597
ER  - 

@article{
author = "Macut, Đuro and Bjekić-Macut, Jelica and Livadas, Sarantis and Stanojlović, Olivera and Hrnčić, Dragan and Rašić-Marković, Aleksandra and Vojnović-Milutinović, Danijela and Mladenović, Violeta and Andrić, Zoran",
year = "2019",
abstract = "Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.",
journal = "Current Pharmaceutical Design",
title = "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome",
number = "38",
volume = "24",
doi = "10.2174/1381612825666190117100751",
pages = "4593-4597"
}

Macut, Đ., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Vojnović-Milutinović, D., Mladenović, V.,& Andrić, Z.. (2019). Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design, 24(38), 4593-4597.
https://doi.org/10.2174/1381612825666190117100751

Macut Đ, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Vojnović-Milutinović D, Mladenović V, Andrić Z. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. in Current Pharmaceutical Design. 2019;24(38):4593-4597.
doi:10.2174/1381612825666190117100751 .

Macut, Đuro, Bjekić-Macut, Jelica, Livadas, Sarantis, Stanojlović, Olivera, Hrnčić, Dragan, Rašić-Marković, Aleksandra, Vojnović-Milutinović, Danijela, Mladenović, Violeta, Andrić, Zoran, "Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome" in Current Pharmaceutical Design, 24, no. 38 (2019):4593-4597,
https://doi.org/10.2174/1381612825666190117100751 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Radosavljević, Vojislav
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Božić Antić, Ivana
AU  - Zdravković, Marija
AU  - Hinić, Saša
AU  - Macut, Đuro
AU  - Žarković, Miloš
PY  - 2016
UR  - http://www.degruyter.com/view/j/jomb.2016.35.issue-4/jomb-2016-0015/jomb-2016-0015.xml
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-84994910742&origin=SingleRecordEmailAlert&txGid=6CE299281CDB840158BFAC52EC5A2E1C.wsnAw8kcdt7IPYLO0V48gA:63#
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2522
AB  - Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.
T2  - Journal of Medical Biochemistry
T1  - Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome
IS  - 4
VL  - 35
DO  - 10.1515/jomb-2016-0015
SP  - 428
EP  - 435
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Radosavljević, Vojislav and Andrić, Zoran and Ilić, Dušan and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Božić Antić, Ivana and Zdravković, Marija and Hinić, Saša and Macut, Đuro and Žarković, Miloš",
year = "2016",
abstract = "Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.",
journal = "Journal of Medical Biochemistry",
title = "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome",
number = "4",
volume = "35",
doi = "10.1515/jomb-2016-0015",
pages = "428-435"
}

Bjekić-Macut, J., Radosavljević, V., Andrić, Z., Ilić, D., Stanojlović, O., Vojnović-Milutinović, D., Božić Antić, I., Zdravković, M., Hinić, S., Macut, Đ.,& Žarković, M.. (2016). Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry, 35(4), 428-435.
https://doi.org/10.1515/jomb-2016-0015

Bjekić-Macut J, Radosavljević V, Andrić Z, Ilić D, Stanojlović O, Vojnović-Milutinović D, Božić Antić I, Zdravković M, Hinić S, Macut Đ, Žarković M. Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry. 2016;35(4):428-435.
doi:10.1515/jomb-2016-0015 .

Bjekić-Macut, Jelica, Radosavljević, Vojislav, Andrić, Zoran, Ilić, Dušan, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Božić Antić, Ivana, Zdravković, Marija, Hinić, Saša, Macut, Đuro, Žarković, Miloš, "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome" in Journal of Medical Biochemistry, 35, no. 4 (2016):428-435,
https://doi.org/10.1515/jomb-2016-0015 . .

TY  - JOUR
AU  - Božić-Antić, Ivana
AU  - Ilić, Dušan
AU  - Bjekić-Macut, Jelica
AU  - Bogavac, Tamara
AU  - Vojnović-Milutinović, Danijela
AU  - Kastratovic-Kotlica, Biljana
AU  - Milić, Nataša
AU  - Stanojlović, Olivera
AU  - Andrić, Zoran
AU  - Macut, Djuro
PY  - 2016
UR  - http://www.eje-online.org/lookup/doi/10.1530/EJE-16-0775
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-85000384361&origin=SingleRecordEmailAlert&dgcid=scalert_sc_search_email&txGid=691E27A4B52E4CB98111082A19AFDEEC.wsnAw8kcdt7IPYLO0V48gA%3A9#
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2482
AB  - Objective: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. Design: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. Methods: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. Results: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. Conclusion: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.
T2  - European Journal of Endocrinology
T1  - Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome
IS  - 6
VL  - 175
DO  - 10.1530/EJE-16-0775
SP  - 551
EP  - 560
ER  - 

@article{
author = "Božić-Antić, Ivana and Ilić, Dušan and Bjekić-Macut, Jelica and Bogavac, Tamara and Vojnović-Milutinović, Danijela and Kastratovic-Kotlica, Biljana and Milić, Nataša and Stanojlović, Olivera and Andrić, Zoran and Macut, Djuro",
year = "2016",
abstract = "Objective: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. Design: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. Methods: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. Results: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. Conclusion: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.",
journal = "European Journal of Endocrinology",
title = "Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome",
number = "6",
volume = "175",
doi = "10.1530/EJE-16-0775",
pages = "551-560"
}

Božić-Antić, I., Ilić, D., Bjekić-Macut, J., Bogavac, T., Vojnović-Milutinović, D., Kastratovic-Kotlica, B., Milić, N., Stanojlović, O., Andrić, Z.,& Macut, D.. (2016). Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. in European Journal of Endocrinology, 175(6), 551-560.
https://doi.org/10.1530/EJE-16-0775

Božić-Antić I, Ilić D, Bjekić-Macut J, Bogavac T, Vojnović-Milutinović D, Kastratovic-Kotlica B, Milić N, Stanojlović O, Andrić Z, Macut D. Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. in European Journal of Endocrinology. 2016;175(6):551-560.
doi:10.1530/EJE-16-0775 .

Božić-Antić, Ivana, Ilić, Dušan, Bjekić-Macut, Jelica, Bogavac, Tamara, Vojnović-Milutinović, Danijela, Kastratovic-Kotlica, Biljana, Milić, Nataša, Stanojlović, Olivera, Andrić, Zoran, Macut, Djuro, "Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome" in European Journal of Endocrinology, 175, no. 6 (2016):551-560,
https://doi.org/10.1530/EJE-16-0775 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Božić-Antić, Ivana
AU  - Vojnović-Milutinović, Danijela
AU  - Stanojlović, Olivera
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Macut, Đuro
PY  - 2015
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/493
AB  - Gojaznost se danas smatra uzrokom nastanka kardiovaskularne bolesti, tipa 2 dijabetesa, osteoartritisa, maligniteta, ali i faktorom koji doprinosi nastanku reproduktivnih poremećaja i problema plodnosti. Postoji povećan relativni rizik za nastanak anovulatornog infertiliteta u žena sa izraženom gojaznošću i produženo vreme do koncepcije. U žena u reproduktivnom periodu gojaznost je povezana sa povećanim rizikom za nastanak hiperandrogenizma i anovulacije, kao što je slučaj u sindromu policističnih jajnika (PCOS) kao najčešćem hiperandrogenom poremećaju. Postoji veliki broj dokaza u prilog postojanja bliskog odnosa adipokina, gojaznosti, metaboličkog sindroma i reproduktivnih posledica. Redukcija težine za 5-10% dovodi do poboljšanja u kliničkim, metaboličkim i reproduktivnim karakteristikama, kao što je slučaj u žena sa PCOS. Primena insulinskih senzitajzera vodi sniženju hiperinsulinemije, insulinske rezistencije, uspostavljanju normalne menstrualne cikličnosti i ovulacije kod značajnog broja žena sa PCOS. Gojaznost može uticati na stimulaciju ovulacije njenim produžavanjem, povećanjem doze gonadotropina, incidence folikularne asinhronije i prekida stimulacije. Hirurško lečenje gojaznosti predstavlja alternativni vid terapije u slučaju kada ni promena načina života ni farmakoterapijske mere ne daju povoljne rezultate. Za sada ne postoji dovoljno dokaza u prilog preporuke da se barijatrijska hirurgija koristi u lečenju gojaznih žena sa PCOS.
T2  - Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor
T1  - Gojaznost i reproduktivna funkcija žene - mehanizmi nastanka i terapijske implikacije
IS  - 56
VL  - 20
SP  - 7
EP  - 14
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_493
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Božić-Antić, Ivana and Vojnović-Milutinović, Danijela and Stanojlović, Olivera and Andrić, Zoran and Ilić, Dušan and Macut, Đuro",
year = "2015, 2015",
abstract = "Gojaznost se danas smatra uzrokom nastanka kardiovaskularne bolesti, tipa 2 dijabetesa, osteoartritisa, maligniteta, ali i faktorom koji doprinosi nastanku reproduktivnih poremećaja i problema plodnosti. Postoji povećan relativni rizik za nastanak anovulatornog infertiliteta u žena sa izraženom gojaznošću i produženo vreme do koncepcije. U žena u reproduktivnom periodu gojaznost je povezana sa povećanim rizikom za nastanak hiperandrogenizma i anovulacije, kao što je slučaj u sindromu policističnih jajnika (PCOS) kao najčešćem hiperandrogenom poremećaju. Postoji veliki broj dokaza u prilog postojanja bliskog odnosa adipokina, gojaznosti, metaboličkog sindroma i reproduktivnih posledica. Redukcija težine za 5-10% dovodi do poboljšanja u kliničkim, metaboličkim i reproduktivnim karakteristikama, kao što je slučaj u žena sa PCOS. Primena insulinskih senzitajzera vodi sniženju hiperinsulinemije, insulinske rezistencije, uspostavljanju normalne menstrualne cikličnosti i ovulacije kod značajnog broja žena sa PCOS. Gojaznost može uticati na stimulaciju ovulacije njenim produžavanjem, povećanjem doze gonadotropina, incidence folikularne asinhronije i prekida stimulacije. Hirurško lečenje gojaznosti predstavlja alternativni vid terapije u slučaju kada ni promena načina života ni farmakoterapijske mere ne daju povoljne rezultate. Za sada ne postoji dovoljno dokaza u prilog preporuke da se barijatrijska hirurgija koristi u lečenju gojaznih žena sa PCOS.",
journal = "Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor",
title = "Gojaznost i reproduktivna funkcija žene - mehanizmi nastanka i terapijske implikacije",
number = "56",
volume = "20",
pages = "7-14",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_493"
}

Bjekić-Macut, J., Božić-Antić, I., Vojnović-Milutinović, D., Stanojlović, O., Andrić, Z., Ilić, D.,& Macut, Đ.. (2015). Gojaznost i reproduktivna funkcija žene - mehanizmi nastanka i terapijske implikacije. in Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor, 20(56), 7-14.
https://hdl.handle.net/21.15107/rcub_ibiss_493

Bjekić-Macut J, Božić-Antić I, Vojnović-Milutinović D, Stanojlović O, Andrić Z, Ilić D, Macut Đ. Gojaznost i reproduktivna funkcija žene - mehanizmi nastanka i terapijske implikacije. in Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor. 2015;20(56):7-14.
https://hdl.handle.net/21.15107/rcub_ibiss_493 .

Bjekić-Macut, Jelica, Božić-Antić, Ivana, Vojnović-Milutinović, Danijela, Stanojlović, Olivera, Andrić, Zoran, Ilić, Dušan, Macut, Đuro, "Gojaznost i reproduktivna funkcija žene - mehanizmi nastanka i terapijske implikacije" in Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor, 20, no. 56 (2015):7-14,
https://hdl.handle.net/21.15107/rcub_ibiss_493 .